Key Slides on ART Options for a Heavily Treatment-Experienced Patient Experiencing Virologic Failure

Download this expert-authored slideset to review guidelines and key data on selecting next-line ART for a heavily-treatment experienced patient with multiclass drug resistance experiencing virologic failure.
Joseph J. Eron, Jr., MD
Monica Gandhi, MD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 664 KB
Released: April 19, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
ViiV Healthcare

Related Content

Vlog from Clinical Care Options (CCO) and Dr. Jehan Budak demonstrating HIV-ASSIST to guide ART selection in a HTE patient with HIV. Review of NRTI, NNRTI, PI, INSTI mutations, and more.

Jehan Budak, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Physician Assistants: maximum of 0.25 hour of AAPA Category ICME credit ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Released: July 27, 2021 Expired: July 26, 2022

Interim results from the Phase II CALIBRATE study of lenacapavir in treatment-naive PLWH, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 24, 2021

Large, retrospective analysis supports the effectiveness and safety of dolutegravir-based regimens among children and adolescents, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

IAS 2021 report from Clinical Care Options (CCO): CUSTOMIZE study shows that HCPs think monthly injectable CAB + RTV LA is feasible and acceptable despite COVID-19 disruptions

Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue